Communiqués Sandoz Group AG

Actions

SDZ

CH1243598427

Produits pharmaceutiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:16 09/05/2025			Varia. 5j.	Varia. 1 janv.
38,03 ^CHF	+2,07%		+3,60%	+2,31%

05/05	RBC relève la note de Sandoz à « surperformance » grâce au lancement de biosimilaires et au faible risque de droits de douane	MT
02/05	Le Swiss Market Index clôture en hausse ; les actions Sandoz brillent	MT

Communiqués

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed	30/04	GL
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications	29/04	GL
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG	15/04	GL
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US	14/04	GL
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US	14/04	GL
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US	14/04	AQ
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility	31/03	GL
Sandoz ascertains obviousness finding against Bayer's Australian Xarelto patent	31/03	AQ
Patent Claim Construction: Understanding Markman Hearings And Litigation Strategy	20/03	AQ
Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected	20/03	AQ
Sandoz reports strong FY 2024 results and Q4 2024 sales	05/03	GL
Sandoz reports strong FY 2024 results and Q4 2024 sales	05/03	AQ
Sandoz launches biosimilar Pyzchiva in the US, offering new treatment for around 12 million patients	25/02	AQ
Samsung Bioepis Announces US Launch of PYZCHIVA, Biosimilar to Stelara	25/02	AQ
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]	24/02	GL
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024	03/02	AQ
Francisco Ballester to retire; Peter Stenico appointed President Region International	03/02	GL
Amgen And Celltrion Settle Denosumab BPCIA Case	31/01	AQ
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference	14/01	GL
Astellas Pharma, Inc. v. Sandoz Inc.	09/01	AQ
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation	17/12	GL
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation	17/12	AQ
Federal Court Denies Motion To Add Infringement Counterclaim To Ustekinumab Impeachment Action	29/11	AQ
Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar	22/11	AQ
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen	21/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

SANDOZ : les prévisions de croissance pèsent sur le second semestre ; perspectives maintenues

Le 30 avril 2025 à 13:44

Sandoz attaque Amgen en justice aux États-Unis

Le 14 avril 2025 à 15:04

Sandoz maintient intactes toutes ses ambitions

Le 06 mars 2025 à 08:22